Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, with or without BCL2 translocations, have been associated with inferior survival in DLBCL. We investigated...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Johnson, Nathalie A., Slack, Graham W., Savage, Kerry J., Connors, Joseph M., Ben-Neriah, Susana, Rogic, Sanja, Scott, David W., Tan, King L., Steidl, Christian, Sehn, Laurie H., Chan, Wing C., Iqbal, Javeed, Meyer, Paul N., Lenz, Georg, Wright, George, Rimsza, Lisa M., Valentino, Carlo, Brunhoeber, Patrick, Grogan, Thomas M., Braziel, Rita M., Cook, James R., Tubbs, Raymond R., Weisenburger, Dennis D., Campo, Elias, Rosenwald, Andreas, Ott, German, Delabie, Jan, Holcroft, Christina, Jaffe, Elaine S., Staudt, Louis M., Gascoyne, Randy D.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2012
Предметы:
ORIGINAL REPORTS
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3454768/
https://ncbi.nlm.nih.gov/pubmed/22851565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.41.0985
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы